Genomenon Unveils Groundbreaking Genomic Knowledgebase Powered by AI
/in Artificial Intelligence/by MaxDinuclear Platinum(II) Complexes: A Promising New Chemotherapy to Treating Prostate Cancer
/in Chemotherapy, Preclinical Research/by MaxNewsletter 5
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the fifth newsletter from the site. I hope I will be like Santa Prostate and bring you some exciting discovery by Christmas! We also have a podcast if you prefer to listen to the newsletter, you can find it […]
Hijacking the Brakes: Scientists Uncover Prostate Cancer’s Growth Secret
/in CRISPR, Preclinical Research/by MaxDietary Intervention Shows Promise in Slowing Prostate Cancer Progression
/in Clinical Trial, Localized/by MaxInvikafusp Alfa: New Hope for Advanced, Anti-PD-1 Resistant Cancers Phase 1 and 2 Trial
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Hope for Hard-to-Treat Cancers: a New TACC3 Inhibitor
/in Clinical Trial, Not PCa related/by MaxTiny Robots Revolutionize Targeted Drug Delivery: Caltech’s Microscopic Marvels
/in Delivery, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026